Biomarkers of Disease Activity, Cure, and Relapse in Tuberculosis

Clinics in Chest Medicine

Volumn 30, Issue 4, 2009, Pages 783-796

  Doherty, T Mark ^a   Wallis, Robert S ^b   Zumla, Alimuddin ^c  

^a STATENS SERUM INSTITUT   (Denmark)

^b PFIZER INC   (United States)

^c ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

Author keywords

Biomarkers; Diagnosis; Tuberculosis

Indexed keywords

BACTERIUM ANTIBODY; BCG VACCINE; CHEMOKINE; CYTOKINE; ISONIAZID; MYCOBACTERIUM ANTIGEN; PEPTIDE;

ADAPTIVE IMMUNITY; ANALYTIC METHOD; BACTERIAL VIRULENCE; BACTERIUM CULTURE; CLINICAL TRIAL; CYTOKINE PRODUCTION; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST; DISEASE ACTIVITY; DISEASE COURSE; DISEASE MARKER; DISEASE PREDISPOSITION; ENDEMIC DISEASE; ENZYME LINKED IMMUNOSORBENT ASSAY; ENZYME LINKED IMMUNOSPOT ASSAY; FALSE POSITIVE RESULT; FLUORESCENCE ACTIVATED CELL SORTING; HUMAN; IMMUNE RESPONSE; IMMUNOGENICITY; IMMUNOLOGICAL PROCEDURES; MICROARRAY ANALYSIS; MORBIDITY; MORTALITY; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; RELAPSE; REVIEW; SYMPTOM; TUBERCULIN TEST; TUBERCULOSIS;

ANTIBODIES, BACTERIAL; BIOLOGICAL MARKERS; CYTOKINES; DIAGNOSIS, DIFFERENTIAL; HUMANS; MYCOBACTERIUM TUBERCULOSIS; TUBERCULIN TEST; TUBERCULOSIS;

EID: 71649100844     PISSN: 02725231     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ccm.2009.08.008     Document Type: Review

References (143)

1. Global tuberculosis control- epidemiology, strategy, financing (2009), World Health Organization, Geneva (Switzerland). http://www.who.int/tb/publications/global_report/en/ Accessed September 18, 2009
2. Andersen P., Doherty T.M., Pai M., et al. The prognosis of latent tuberculosis: can disease be predicted?. Trends Mol Med 13 5 (2007) 175-182
3. Manabe Y.C., and Bishai W.R. Latent Mycobacterium tuberculosis-persistence, patience, and winning by waiting. Nat Med 6 12 (2000) 1327-1329
4. Morrison J., Pai M., and Hopewell P.C. Tuberculosis and latent tuberculosis infection in close contacts of people with pulmonary tuberculosis in low-income and middle-income countries: a systematic review and meta-analysis. Lancet Infect Dis 8 6 (2008) 359-368
5. Stewart G.R., Robertson B.D., and Young D.B. Tuberculosis: a problem with persistence. Nat Rev Microbiol 1 2 (2003) 97-105
6. Breen R.A., Leonard O., Perrin F.M., et al. How good are systemic symptoms and blood inflammatory markers at detecting individuals with tuberculosis?. Int J Tuberc Lung Dis 12 1 (2008) 44-49
7. Marais B., Schaaf S., Hesseling A., et al. Tuberculosis case definition: time for critical re-assessment?. Int J Tuberc Lung Dis 12 10 (2008) 1217
8. Dietrich J., and Doherty T.M. Interaction of Mycobacterium tuberculosis with the host: consequences for vaccine development. APMIS 117 5-6 (2009) 440-457
9. Russell D.G. Mycobacterium tuberculosis: here today, and here tomorrow. Nat Rev Mol Cell Biol 2 8 (2001) 569-577
10. Rachman H., Strong M., Schaible U., et al. Mycobacterium tuberculosis gene expression profiling within the context of protein networks. Microbes Infect 8 3 (2006) 747-757
11. Rachman H., Strong M., Ulrichs T., et al. Unique transcriptome signature of Mycobacterium tuberculosis in pulmonary tuberculosis. Infect Immun 74 2 (2006) 1233-1242
12. Rustad T.R., Harrell M.I., Liao R., et al. The enduring hypoxic response of Mycobacterium tuberculosis. PLoS One 3 1 (2008) e1502
13. Edwards P.Q., and Edwads L.B. Story of the tuberculin test from an epidemiologic viewpoint. Am Rev Respir Dis 81 1 Pt 2): (1960) 1-47
14. Judson F.N., and Feldman R.A. Mycobacterial skin tests in humans 12 years after infection with Mycobacterium marinum. Am Rev Respir Dis 109 5 (1974) 544-547
15. Hill P.C., Brookes R.H., Adetifa I.M., et al. Comparison of enzyme-linked immunospot assay and tuberculin skin test in healthy children exposed to Mycobacterium tuberculosis. Pediatrics 117 5 (2006) 1542-1548
16. Mori T., Sakatani M., Yamagishi F., et al. Specific detection of tuberculosis infection: an interferon-gamma-based assay using new antigens. Am J Respir Crit Care Med 170 1 (2004) 59-64
17. Kang Y.A., Lee H.W., Yoon H.I., et al. Discrepancy between the tuberculin skin test and the whole-blood interferon gamma assay for the diagnosis of latent tuberculosis infection in an intermediate tuberculosis-burden country. JAMA 293 22 (2005) 2756-2761
18. Mack U., Migliori G.B., Sester M., et al. LTBI: latent tuberculosis infection or lasting immune responses to M. tuberculosis? A TBNET consensus statement. Eur Respir J 33 5 (2009) 956-973
19. Jeyakumar D. Tuberculin reactivity and subsequent development of tuberculosis in a cohort of student nurses. Med J Malaysia 54 4 (1999) 492-495
20. Leung C.C., Yew W.W., Chang K.C., et al. Risk of active tuberculosis among schoolchildren in Hong Kong. Arch Pediatr Adolesc Med 160 3 (2006) 247-251
21. Jasmer R.M., Nahid P., and Hopewell P.C. Clinical practice. Latent tuberculosis infection. N Engl J Med 347 23 (2002) 1860-1866
22. Berkel G.M., Cobelens F.G., de Vries G., et al. Tuberculin skin test: estimation of positive and negative predictive values from routine data. Int J Tuberc Lung Dis 9 3 (2005) 310-316
23. Menzies D, Doherty TM. Diagnosis of latent tuberculosis infection. In: Raviglione M, editor. Reichman and Hershfield's tuberculosis: a comprehensive, international approach. 3rd edition. vol. 1. 2007. New York: Informa Healthcare; 2007. p. 215-51.
24. Pollock J.M., McNair J., Bassett H., et al. Specific delayed-type hypersensitivity responses to ESAT-6 identify tuberculosis-infected cattle. J Clin Microbiol 41 5 (2003) 1856-1860
25. Arend S.M., Franken W.P., Aggerbeck H., et al. Double-blind randomized phase I study comparing rdESAT-6 to tuberculin as skin test reagent in the diagnosis of tuberculosis infection. Tuberculosis (Edinb) 88 3 (2008) 249-261
26. Lillebaek T., Bergstedt W., Tingskov P.N., et al. Risk of sensitization in healthy adults following repeated administration of rdESAT-6 skin test reagent by the Mantoux injection technique. Tuberculosis (Edinb) 89 2 (2009) 158-162
27. Weldingh K., and Andersen P. ESAT-6/CFP10 skin test predicts disease in M. tuberculosis-infected guinea pigs. PLoS One 3 4 (2008) e1978
28. Elhay M.J., Oettinger T., and Andersen P. Delayed-type hypersensitivity responses to ESAT-6 and MPT64 from Mycobacterium tuberculosis in the guinea pig. Infect Immun 66 7 (1998) 3454-3456
29. Tavares R.C., Salgado J., Moreira V.B., et al. Interferon gamma response to combinations 38 kDa/CFP-10, 38 kDa/MPT-64, ESAT-6/MPT-64 and ESAT-6/CFP-10, each related to a single recombinant protein of Mycobacterium tuberculosis in individuals from tuberculosis endemic areas. Microbiol Immunol 51 3 (2007) 289-296
30. Li H., Ulstrup J.C., Jonassen T.O., et al. Evidence for absence of the MPB64 gene in some substrains of Mycobacterium bovis BCG. Infect Immun 61 5 (1993) 1730-1734
31. Sarrazin H., Wilkinson K.A., Andersson J., et al. Association between tuberculin skin test reactivity, the memory CD4 cell subset, and circulating FoxP3-expressing cells in HIV-infected persons. J Infect Dis 199 5 (2009) 702-710
32. Stein C.M., Zalwango S., Malone L.L., et al. Genome scan of M. tuberculosis infection and disease in Ugandans. PLoS One 3 12 (2008) e4094
33. Mortatti R.C., and Maia L.C. Immune response to BCG-Moreau (Rio de Janeiro) strain. Spectrum of delayed hypersensitivity in genetically defined mice. FEMS Microbiol Immunol 1 8-9 (1989) 491-497
34. Gallant C.J., Malik S., Jabado N., et al. Reduced in vitro functional activity of human NRAMP1 (SLC11A1) allele that predisposes to increased risk of pediatric tuberculosis disease. Genes Immun 8 8 (2007) 691-698
35. Patel S.Y., Doffinger R., Barcenas-Morales G., et al. Genetically determined susceptibility to mycobacterial infection. J Clin Pathol 61 9 (2008) 1006-1012
36. Gomez-Reino J.J., Carmona L., Valverde V.R., et al. Treatment of rheumatoid arthritis with tumor necrosis factor inhibitors may predispose to significant increase in tuberculosis risk: a multicenter active-surveillance report. Arthritis Rheum 48 8 (2003) 2122-2127
37. Harris J., Hope J.C., and Keane J. Tumor necrosis factor blockers influence macrophage responses to Mycobacterium tuberculosis. J Infect Dis 198 (2008) 1842-1850
38. Ottenhoff T.H., Verreck F.A., Hoeve M.A., et al. Control of human host immunity to mycobacteria. Tuberculosis (Edinb) 85 1-2 (2005) 53-64
39. Flynn J.L., Chan J., Triebold K.J., et al. An essential role for interferon gamma in resistance to Mycobacterium tuberculosis infection. J Exp Med 178 6 (1993) 2249-2254
40. Hussain R., Talat N., Shahid F., et al. Longitudinal tracking of cytokines after acute exposure to tuberculosis: association of distinct cytokine patterns with protection and disease development. Clin Vaccine Immunol 14 12 (2007) 1578-1586
41. Carrara S., Vincenti D., Petrosillo N., et al. Use of a T cell-based assay for monitoring efficacy of antituberculosis therapy. Clin Infect Dis 38 5 (2004) 754-756
42. Flynn J.L., Goldstein M.M., Chan J., et al. Tumor necrosis factor-alpha is required in the protective immune response against Mycobacterium tuberculosis in mice. Immunity 2 6 (1995) 561-572
43. Jacobs M., Togbe D., Fremond C., et al. Tumor necrosis factor is critical to control tuberculosis infection. Microbes Infect 9 5 (2007) 623-628
44. Stein C.M., Zalwango S., Chiunda A.B., et al. Linkage and association analysis of candidate genes for TB and TNFalpha cytokine expression: evidence for association with IFNGR1, IL-10, and TNF receptor 1 genes. Hum Genet 121 6 (2007) 663-673
45. Fernandez-Botran R. Soluble cytokine receptors: novel immunotherapeutic agents. Expert Opin Investig Drugs 9 3 (2000) 497-514
46. Tsao T.C., Hong J., Li L.F., et al. Imbalances between tumor necrosis factor-alpha and its soluble receptor forms, and interleukin-1beta and interleukin-1 receptor antagonist in BAL fluid of cavitary pulmonary tuberculosis. Chest 117 1 (2000) 103-109
47. Brahmbhatt S., Black G.F., Carroll N.M., et al. Immune markers measured before treatment predict outcome of intensive phase tuberculosis therapy. Clin Exp Immunol 146 2 (2006) 243-252
48. Clay H., Volkman H.E., and Ramakrishnan L. Tumor necrosis factor signaling mediates resistance to mycobacteria by inhibiting bacterial growth and macrophage death. Immunity 29 2 (2008) 283-294
49. Doherty T.M., Demissie A., Menzies D., et al. Effect of sample handling on analysis of cytokine responses to Mycobacterium tuberculosis in clinical samples using ELISA, ELISPOT and quantitative PCR. J Immunol Methods 298 1-2 (2005) 129-141
50. Dinnes J., Deeks J., Kunst H., et al. A systematic review of rapid diagnostic tests for the detection of tuberculosis infection. Health Technol Assess 11 3 (2007) 1-196
51. Watkins R.E., Brennan R., and Plant A.J. Tuberculin reactivity and the risk of tuberculosis: a review. Int J Tuberc Lung Dis 4 10 (2000) 895-903
52. Diel R., Loddenkemper R., Meywald-Walter K., et al. Predictive value of a whole blood IFN-gamma assay for the development of active tuberculosis disease after recent infection with Mycobacterium tuberculosis. Am J Respir Crit Care Med 177 10 (2008) 1164-1170
53. Doherty T.M., Demissie A., Olobo J., et al. Immune responses to the Mycobacterium tuberculosis-specific antigen ESAT-6 signal subclinical infection among contacts of tuberculosis patients. J Clin Microbiol 40 2 (2002) 704-706
54. Higuchi K., Harada N., Fukazawa K., et al. Relationship between whole-blood interferon-gamma responses and the risk of active tuberculosis. Tuberculosis (Edinb) 88 3 (2008) 244-248
55. Ewer K., Millington K.A., Deeks J.J., et al. Dynamic antigen-specific T Cell responses after point-source exposure to Mycobacterium tuberculosis. Am J Respir Crit Care Med 174 (2006) 831-839
56. Wedlock D.N., Denis M., Vordermeier H.M., et al. Vaccination of cattle with Danish and Pasteur strains of Mycobacterium bovis BCG induce different levels of IFNgamma post-vaccination, but induce similar levels of protection against bovine tuberculosis. Vet Immunol Immunopathol 118 1-2 (2007) 50-58
57. Winek J., Rowinska-Zakrzewska E., Demkow U., et al. Interferon gamma production in the course of Mycobacterium tuberculosis infection. J Physiol Pharmacol 59 Suppl 6 (2008) 751-759
58. Yeboah-Manu D., Peduzzi E., Mensah-Quainoo E., et al. Systemic suppression of interferon-gamma responses in Buruli ulcer patients resolves after surgical excision of the lesions caused by the extracellular pathogen Mycobacterium ulcerans. J Leukoc Biol 79 6 (2006) 1150-1156
59. Ruhwald M., Bjerregaard-Andersen M., Rabna P., et al. IP-10, MCP-1, MCP-2, MCP-3, and IL-1RA hold promise as biomarkers for infection with M. tuberculosis in a whole blood based T-cell assay. BMC Res Notes 2 (2009) 19
60. Wassie L., Demissie A., Aseffa A., et al. Ex vivo cytokine mRNA levels correlate with changing clinical status of Ethiopian TB patients and their contacts over time. PLoS One 3 1 (2008) e1522
61. Ordway D.J., Costa L., Martins M., et al. Increased Interleukin-4 production by CD8 and gammadelta T cells in health-care workers is associated with the subsequent development of active tuberculosis. J Infect Dis 190 4 (2004) 756-766
62. Siawaya J.F., Bapela N.B., Ronacher K., et al. Differential expression of interleukin-4 (IL-4) and IL-4 delta 2 mRNA, but not transforming growth factor beta (TGF-beta), TGF-beta RII, Foxp3, gamma interferon, T-bet, or GATA-3 mRNA, in patients with fast and slow responses to antituberculosis treatment. Clin Vaccine Immunol 15 8 (2008) 1165-1170
63. Demissie A., Abebe M., Aseffa A., et al. Healthy individuals that control a latent infection with Mycobacterium tuberculosis express high levels of Th1 cytokines and the IL-4 antagonist IL-4delta2. J Immunol 172 11 (2004) 6938-6943
64. Orsini B., Vivas J.R., Ottanelli B., et al. Human gastric epithelium produces IL-4 and IL-4delta2 isoform only upon Helicobacter pylori infection. Int J Immunopathol Pharmacol 20 4 (2007) 809-818
65. Seah G.T., Gao P.S., Hopkin J.M., et al. Interleukin-4 and its alternatively spliced variant (IL-4delta2) in patients with atopic asthma. Am J Respir Crit Care Med 164 6 (2001) 1016-1018
66. Rhodes S.G., Sawyer J., Whelan A.O., et al. Is interleukin-4delta3 splice variant expression in bovine tuberculosis a marker of protective immunity?. Infect Immun 75 6 (2007) 3006-3013
67. Leung W.L., Law K.L., Leung V.S., et al. Comparison of intracellular cytokine flow cytometry and an enzyme immunoassay for evaluation of cellular immune response to active tuberculosis. Clin Vaccine Immunol 16 3 (2009) 344-351
68. Winthrop K.L., and Daley C.L. A novel assay for screening patients for latent tuberculosis infection prior to anti-TNF therapy. Nat Clin Pract Rheumatol 4 9 (2008) 456-457
69. Rosas-Taraco A.G., Salinas-Carmona M.C., Revol A., et al. Expression of CDllc in blood monocytes as biomarker for favorable response to antituberculosis treatment. Arch Med Res 40 2 (2009) 128-131
70. Veenstra H., Baumann R., Carroll N.M., et al. Changes in leucocyte and lymphocyte subsets during tuberculosis treatment; prominence of CD3dimCD56+ natural killer T cells in fast treatment responders. Clin Exp Immunol 145 2 (2006) 252-260
71. Seiler P., Aichele P., Bandermann S., et al. Early granuloma formation after aerosol Mycobacterium tuberculosis infection is regulated by neutrophils via CXCR3-signaling chemokines. Eur J Immunol 33 10 (2003) 2676-2686
72. Tsai M.C., Chakravarty S., Zhu G., et al. Characterization of the tuberculous granuloma in murine and human lungs: cellular composition and relative tissue oxygen tension. Cell Microbiol 8 2 (2006) 218-232
73. Seder R.A., Darrah P.A., and Roederer M. T-cell quality in memory and protection: implications for vaccine design. Nat Rev Immunol 8 4 (2008) 247-258
74. Forbes E.K., Sander C., Ronan E.O., et al. Multifunctional, high-level cytokine-producing Th1 cells in the lung, but not spleen, correlate with protection against Mycobacterium tuberculosis aerosol challenge in mice. J Immunol 181 7 (2008) 4955-4964
75. Day C.L., Mkhwanazi N., Reddy S., et al. Detection of polyfunctional Mycobacterium tuberculosis-specific T cells and association with viral load in HIV-1-infected persons. J Infect Dis 197 7 (2008) 990-999
76. Mueller H., Detjen A.K., Schuck S.D., et al. Mycobacterium tuberculosis-specific CD4+, IFNgamma+, and TNFalpha+ multifunctional memory T cells coexpress GM-CSF. Cytokine 43 2 (2008) 143-148
77. Roberts T., Beyers N., Aguirre A., et al. Immunosuppression during active tuberculosis is characterized by decreased interferon- gamma production and CD25 expression with elevated forkhead box P3, transforming growth factor- beta, and interleukin-4 mRNA levels. J Infect Dis 195 6 (2007) 870-878
78. Chen X., Zhou B., Li M., et al. CD4(+)CD25(+)FoxP3(+) regulatory T cells suppress Mycobacterium tuberculosis immunity in patients with active disease. Clin Immunol 123 1 (2007) 50-59
79. Sharma P.K., Saha P.K., Singh A., et al. FoxP3+ regulatory T cells suppress effector T cell function at pathologic site in miliary tuberculosis. Am J Respir Crit Care Med 179 (2009) 1061-1070
80. Belkaid Y., and Oldenhove G. Tuning microenvironments: induction of regulatory T cells by dendritic cells. Immunity 29 3 (2008) 362-371
81. Guyot-Revol V., Innes J.A., Hackforth S., et al. Regulatory T cells are expanded in blood and disease sites in patients with tuberculosis. Am J Respir Crit Care Med 173 7 (2006) 803-810
82. Li L., Lao S.H., and Wu C.Y. Increased frequency of CD4(+)CD25(high) Treg cells inhibit BCG-specific induction of IFN-gamma by CD4(+) T cells from TB patients. Tuberculosis (Edinb) 87 6 (2007) 526-534
83. Ribeiro-Rodrigues R., Resende Co T., Rojas R., et al. A role for CD4+CD25+ T cells in regulation of the immune response during human tuberculosis. Clin Exp Immunol 144 1 (2006) 25-34
84. Demissie A., Leyten E.M., Abebe M., et al. Recognition of stage-specific mycobacterial antigens differentiates between acute and latent infections with Mycobacterium tuberculosis. Clin Vaccine Immunol 13 2 (2006) 179-186
85. Hougardy J.M., Schepers K., Place S., et al. Heparin-binding-hemagglutinin-induced IFN-gamma release as a diagnostic tool for latent tuberculosis. PLoS One 2 10 (2007) e926
86. Hougardy J.M., Place S., Hildebrand M., et al. Regulatory T cells depress immune responses to protective antigens in active tuberculosis. Am J Respir Crit Care Med 176 4 (2007) 409-416
87. Djoba Siawaya J.F., Bapela N.B., Ronacher K., et al. Immune parameters as markers of tuberculosis extent of disease and early prediction of anti-tuberculosis chemotherapy response. J Infect 56 5 (2008) 340-347
88. Bajaj G., Rattan A., and Ahmad P. Prognostic value of 'C' reactive protein in tuberculosis. Indian Pediatr 26 10 (1989) 1010-1013
89. Scott G.M., Murphy P.G., and Gemidjioglu M.E. Predicting deterioration of treated tuberculosis by corticosteroid reserve and C-reactive protein. J Infect 21 1 (1990) 61-69
90. Baynes R., Bezwoda W., Bothwell T., et al. The non-immune inflammatory response: serial changes in plasma iron, iron-binding capacity, lactoferrin, ferritin and C-reactive protein. Scand J Clin Lab Invest 46 7 (1986) 695-704
91. Tozkoparan E., Deniz O., Cakir E., et al. The diagnostic values of serum, pleural fluid and urine neopterin measurements in tuberculous pleurisy. Int J Tuberc Lung Dis 9 9 (2005) 1040-1045
92. Aung H., Wu M., Johnson J.L., et al. Bioactivation of latent transforming growth factor beta1 by Mycobacterium tuberculosis in human mononuclear phagocytes. Scand J Immunol 61 6 (2005) 558-565
93. Djoba Siawaya J.F., Ruhwald M., Eugen-Olsen J., et al. Correlates for disease progression and prognosis during concurrent HIV/TB infection. Int J Infect Dis 11 4 (2007) 289-299
94. Eugen-Olsen J., Gustafson P., Sidenius N., et al. The serum level of soluble urokinase receptor is elevated in tuberculosis patients and predicts mortality during treatment: a community study from Guinea-Bissau. Int J Tuberc Lung Dis 6 8 (2002) 686-692
95. Lawn S.D., Harries A.D., Anglaret X., et al. Early mortality among adults accessing antiretroviral treatment programmes in sub-Saharan Africa. AIDS 22 15 (2008) 1897-1908
96. Sidenius N., Sier C.F., Ullum H., et al. Serum level of soluble urokinase-type plasminogen activator receptor is a strong and independent predictor of survival in human immunodeficiency virus infection. Blood 96 13 (2000) 4091-4095
97. Ghosh S., and Saxena R.K. Early effect of Mycobacterium tuberculosis infection on Mac-1 and ICAM-1 expression on mouse peritoneal macrophages. Exp Mol Med 36 5 (2004) 387-395
98. Melis M., Pace E., Siena L., et al. Biologically active intercellular adhesion molecule-1 is shed as dimers by a regulated mechanism in the inflamed pleural space. Am J Respir Crit Care Med 167 8 (2003) 1131-1138
99. Demir T., Yalcinoz C., Keskinel I., et al. sICAM-1 as a serum marker in the diagnosis and follow-up of treatment of pulmonary tuberculosis. Int J Tuberc Lung Dis 6 2 (2002) 155-159
100. Mukae H., Ashitani J., Tokojima M., et al. Elevated levels of circulating adhesion molecules in patients with active pulmonary tuberculosis. Respirology 8 3 (2003) 326-331
101. Balcewicz-Sablinska M.K., Keane J., Kornfeld H., et al. Pathogenic Mycobacterium tuberculosis evades apoptosis of host macrophages by release of TNF-R2, resulting in inactivation of TNF-alpha. J Immunol 161 5 (1998) 2636-2641
102. Steingart K.R., Henry M., Laal S., et al. Commercial serological antibody detection tests for the diagnosis of pulmonary tuberculosis: a systematic review. PLoS Med 4 6 (2007) e202
103. Steingart K.R., Henry M., Laal S., et al. A systematic review of commercial serological antibody detection tests for the diagnosis of extrapulmonary tuberculosis. Thorax 62 10 (2007) 911-918
104. Gennaro M.L., Affouf M., Kanaujia G.V., et al. Antibody markers of incident tuberculosis among HIV-infected adults in the USA: a historical prospective study. Int J Tuberc Lung Dis 11 6 (2007) 624-631
105. Singh K.K., Dong Y., Belisle J.T., et al. Antigens of Mycobacterium tuberculosis recognized by antibodies during incipient, subclinical tuberculosis. Clin Diagn Lab Immunol 12 2 (2005) 354-358
106. Bahk Y.Y., Kim S.A., Kim J.S., et al. Antigens secreted from Mycobacterium tuberculosis: identification by proteomics approach and test for diagnostic marker. Proteomics 4 11 (2004) 3299-3307
107. Weldingh K., Rosenkrands I., Okkels L.M., et al. Assessing the serodiagnostic potential of 35 Mycobacterium tuberculosis proteins and identification of four novel serological antigens. J Clin Microbiol 43 1 (2005) 57-65
108. Sartain M.J., Slayden R.A., Singh K.K., et al. Disease state differentiation and identification of tuberculosis biomarkers via native antigen array profiling. Mol Cell Proteomics 5 11 (2006) 2102-2113
109. Khan I.H., Ravindran R., Yee J., et al. Profiling antibodies to Mycobacterium tuberculosis by multiplex microbead suspension arrays for serodiagnosis of tuberculosis. Clin Vaccine Immunol 15 3 (2008) 433-438
110. Gaseitsiwe S., Valentini D., Mahdavifar S., et al. Pattern recognition in pulmonary tuberculosis defined by high content peptide microarray chip analysis representing 61 proteins from M. tuberculosis. PLoS One 3 12 (2008) e3840
111. Wu-Hsieh B.A., Chen C.K., Chang J.H., et al. Long-lived immune response to early secretory antigenic target 6 in individuals who had recovered from tuberculosis. Clin Infect Dis 33 8 (2001) 1336-1340
112. Sauzullo I., Mengoni F., Lichtner M., et al. In vivo and in vitro effects of antituberculosis treatment on mycobacterial Interferon-gamma T cell response. PLoS One 4 4 (2009) e5187
113. Maher D., Harries A., and Getahun H. Tuberculosis and HIV interaction in sub-Saharan Africa: impact on patients and programmes; implications for policies. Trop Med Int Health 10 8 (2005) 734-742
114. Wallis R.S., Phillips M., Johnson J.L., et al. Inhibition of isoniazid-induced expression of Mycobacterium tuberculosis antigen 85 in sputum: potential surrogate marker in tuberculosis chemotherapy trials. Antimicrob Agents Chemother 45 4 (2001) 1302-1304
115. Desjardin L.E., Perkins M.D., Wolski K., et al. Measurement of sputum Mycobacterium tuberculosis messenger RNA as a surrogate for response to chemotherapy. Am J Respir Crit Care Med 160 1 (1999) 203-210
116. Garbe T.R., Hibler N.S., and Deretic V. Isoniazid induces expression of the antigen 85 complex in Mycobacterium tuberculosis. Antimicrob Agents Chemother 40 7 (1996) 1754-1756
117. Chakraborty N., Bhattacharyya S., De C., et al. A rapid immunochromatographic assay for the detection of Mycobacterium tuberculosis antigens in pulmonary samples from HIV seropositive patients and its comparison with conventional methods. J Microbiol Methods 76 1 (2009) 12-17
118. El-Masry S., El-Kady I., Zaghloul M.H., et al. Rapid and simple detection of a mycobacterium circulating antigen in serum of pulmonary tuberculosis patients by using a monoclonal antibody and Fast-Dot-ELISA. Clin Biochem 41 3 (2008) 145-151
119. Baba K., Dyrhol-Riise A.M., Sviland L., et al. Rapid and specific diagnosis of tuberculous pleuritis with immunohistochemistry by detecting Mycobacterium tuberculosis complex specific antigen MPT64 in patients from a HIV endemic area. Appl Immunohistochem Mol Morphol 16 6 (2008) 554-561
120. Goel M.M., and Budhwar P. Species-specific immunocytochemical localization of Mycobacterium tuberculosis complex in fine needle aspirates of tuberculous lymphadenitis using antibody to 38 kDa immunodominant protein antigen. Acta Cytol 52 4 (2008) 424-433
121. Attallah A.M., Osman S., Saad A., et al. Application of a circulating antigen detection immunoassay for laboratory diagnosis of extra-pulmonary and pulmonary tuberculosis. Clin Chim Acta 356 1-2 (2005) 58-66
122. Bera S., Shende N., Kumar S., et al. Detection of antigen and antibody in childhood tuberculous meningitis. Indian J Pediatr 73 8 (2006) 675-679
123. Choudhry V., and Saxena R.K. Detection of Mycobacterium tuberculosis antigens in urinary proteins of tuberculosis patients. Eur J Clin Microbiol Infect Dis 21 1 (2002) 1-5
124. Gopinath K., and Singh S. Urine as an adjunct specimen for the diagnosis of active pulmonary tuberculosis. Int J Infect Dis 13 3 (2009) 374-379
125. Cannas A., Goletti D., Girardi E., et al. Mycobacterium tuberculosis DNA detection in soluble fraction of urine from pulmonary tuberculosis patients. Int J Tuberc Lung Dis 12 2 (2008) 146-151
126. Napolitano D.R., Pollock N., Kashino S.S., et al. Identification of Mycobacterium tuberculosis ornithine carboamyltransferase in urine as a possible molecular marker of active pulmonary tuberculosis. Clin Vaccine Immunol 15 4 (2008) 638-643
127. Torrea G., Van de Perre P., Ouedraogo M., et al. PCR-based detection of the Mycobacterium tuberculosis complex in urine of HIV-infected and uninfected pulmonary and extrapulmonary tuberculosis patients in Burkina Faso. J Med Microbiol 54 Pt 1 (2005) 39-44
128. Boehme C., Molokova E., Minja F., et al. Detection of mycobacterial lipoarabinomannan with an antigen-capture ELISA in unprocessed urine of Tanzanian patients with suspected tuberculosis. Trans R Soc Trop Med Hyg 99 12 (2005) 893-900
129. Hamasur B., Bruchfeld J., Haile M., et al. Rapid diagnosis of tuberculosis by detection of mycobacterial lipoarabinomannan in urine. J Microbiol Methods 45 1 (2001) 41-52
130. Tessema T.A., Bjune G., Hamasur B., et al. Circulating antibodies to lipoarabinomannan in relation to sputum microscopy, clinical features and urinary anti-lipoarabinomannan detection in pulmonary tuberculosis. Scand J Infect Dis 34 2 (2002) 97-103
131. Pavlou A.K., Magan N., Jones J.M., et al. Detection of Mycobacterium tuberculosis (TB) in vitro and in situ using an electronic nose in combination with a neural network system. Biosens Bioelectron 20 3 (2004) 538-544
132. Fend R., Kolk A.H., Bessant C., et al. Prospects for clinical application of electronic-nose technology to early detection of Mycobacterium tuberculosis in culture and sputum. J Clin Microbiol 44 6 (2006) 2039-2045
133. Syhre M., and Chambers S.T. The scent of Mycobacterium tuberculosis. Tuberculosis (Edinb) 88 4 (2008) 317-323
134. Phillips M., Cataneo R.N., Condos R., et al. Volatile biomarkers of pulmonary tuberculosis in the breath. Tuberculosis (Edinb) 87 1 (2007) 44-52
135. Agranoff D., Fernandez-Reyes D., Papadopoulos M.C., et al. Identification of diagnostic markers for tuberculosis by proteomic fingerprinting of serum. Lancet 368 9540 (2006) 1012-1021
136. Kaufmann S.H., and Parida S.K. Tuberculosis in Africa: learning from pathogenesis for biomarker identification. Cell Host Microbe 4 3 (2008) 219-228
137. Mistry R., Cliff J.M., Clayton C.L., et al. Gene-expression patterns in whole blood identify subjects at risk for recurrent tuberculosis. J Infect Dis 195 3 (2007) 357-365
138. Schaible U.E., Collins H.L., Priem F., et al. Correction of the iron overload defect in beta-2-microglobulin knockout mice by lactoferrin abolishes their increased susceptibility to tuberculosis. J Exp Med 196 11 (2002) 1507-1513
139. Barth E., Fischer G., Schneider E.M., et al. Peaks of endogenous G-CSF serum concentrations are followed by an increase in respiratory burst activity of granulocytes in patients with septic shock. Cytokine 17 5 (2002) 275-284
140. Schimmoller F., Simon I., and Pfeffer S.R. Rab GTPases, directors of vesicle docking. J Biol Chem 273 35 (1998) 22161-22164
141. Brumell J.H., and Scidmore M.A. Manipulation of rab GTPase function by intracellular bacterial pathogens. Microbiol Mol Biol Rev 71 4 (2007) 636-652
142. Wu B., Huang C., Kato-Maeda M., et al. Messenger RNA expression of IL-8, FOXP3, and IL-12beta differentiates latent tuberculosis infection from disease. J Immunol 178 6 (2007) 3688-3694
143. Doherty M., Wallis R.S., and Zumla A. Biomarkers for tuberculosis disease status and diagnosis. Curr Opin Pulm Med 15 3 (2009) 181-187